Flow cytometric analysis of CAR (FMC63 scFv) transfected 293T (Human embryonic kidney epithelial cell (Right panel) or untrasfected 293T (Left panel) labelling FMC63 antibody at 1/2000 (0.1 μg) dilution. Goat Anti-Rabbit IgG Alexa Fluor® 488 was used as the secondary antibody.
Product Details
Product Details
Product Specification
Host | Rabbit |
Antigen | FMC63 scFv |
Immunogen | Recombinant Protein |
Clone Number | S-2163-77 |
Antibody Type | Recombinant mAb |
Isotype | IgG |
Application | FCM |
Purification | Protein A |
Concentration | 2 mg/ml |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4 |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
application | dilution | species |
FCM | 1:2000 | Species independent |
Background
FMC63 scFv (single-chain variable fragment) is a recombinant protein derived from the variable regions (VH and VL) of the anti-CD19 monoclonal antibody FMC63, linked by a flexible peptide spacer (e.g., (Gly₄Ser)₃). It specifically binds to the B-cell surface antigen CD19 with high affinity (KD ~1-10 nM) and is a key targeting component in FDA-approved CAR-T therapies, such as Kymriah®. The humanized FMC63 scFv retains potent antigen recognition while minimizing immunogenicity, making it highly effective in treating B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Ongoing research focuses on optimizing its affinity, stability, and functionality to enhance the safety and efficacy of CAR-T cell therapies.
Picture
Picture
FC
